An American pharmaceutical company has warned about the cessation of supplies to Russia of the drug Zepatier for the treatment of hepatitis C. This is one of the most popular drugs for the treatment of this disease – it accounted for about 20% of government purchases in the past, 2022. Until 2030, Zepatier is under patent protection, and there are no analogues of this drug in our country.
Does this mean that hepatitis C patients will go untreated? aif.ru told about this President of the Scientific Society of Gastroenterologists Professor Leonid Lazebnik:
“Patients will definitely not be left without medicines. Zepatier is far from the only remedy for hepatitis C. The choice of drugs that are used to treat this disease is quite wide. After the appearance of the zepatier, they faded into the background, but their release did not stop.
Since deliveries will continue until the end of 2024, there is no doubt that by this time the optimal solution will be found in Russia, which, in particular, includes the production of analogues of this drug.
Source: aif.ru
